anti-tnfr2 monoclonal antibody bi-1808
Generic: Anti-TNFR2 Monoclonal Antibody BI-1808
anti-tnfr2 monoclonal antibody bi-1808: 1 clinical trial tracked.
anti-tnfr2 monoclonal antibody bi-1808 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about anti-tnfr2 monoclonal antibody bi-1808, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (1)
Phase 1/2a Open-Label, Dose-Escalation, Multicenter, FIH, Consecutive-Cohort, Clinical Trial of BI-1808, a Monoclonal Antibody to TNFR 2 as a Single Agent and in Combination With Pembrolizumab (MK-3475-D20) in Subjects With Advanced Malignancies
Primary endpoint: Occurrence of adverse events (AEs)
Interventionalopen176 targetStarted 2021-01Completion 2028-0125 sites · Denmark, Hungary, Russia, Spain…BioInvent International AB